CVR number 31591414
Industry 72.1100 Research and experimental development on biotechnology

VISIANA ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.2% 1.2% 1.2% 1.2% 1.2%  
Bankruptcy risk  3.0% 4.3% 2.9% 3.5% 5.1%  
Credit score (0-100)  58 47 57 53 42  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  3,278 4,940 5,158 5,623 5,584  
EBITDA  748 79.7 672 936 125  
EBIT  717 65.5 672 936 125  
Pre-tax profit (PTP)  708.4 41.5 656.1 938.5 127.2  
Net earnings  556.4 30.2 547.6 731.7 99.1  
Pre-tax profit without non-rec. items  708 41.5 656 938 127  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  14.2 0.0 0.0 0.0 0.0  
Shareholders equity total  1,247 1,277 1,825 2,556 1,455  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 256  
Balance sheet total (assets)  2,206 2,685 3,308 2,782 2,338  
Net Debt  -459 -344 -230 -484 38.9  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  3,278 4,940 5,158 5,623 5,584  
Gross profit growth  -1.7% 50.7% 4.4% 9.0% -0.7%  
Employees  3 4 6 7 8  
Employee growth %  0.0% 33.3% 50.0% 16.7% 14.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,206 2,685 3,308 2,782 2,338  
Balance sheet change%  -5.8% 21.7% 23.2% -15.9% -16.0%  
Added value  747.7 79.7 672.3 936.1 125.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -61 -28 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  21.9% 1.3% 13.0% 16.6% 2.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  31.6% 2.7% 22.4% 30.9% 5.0%  
ROI %  58.8% 5.2% 43.2% 43.0% 6.0%  
ROE %  45.7% 2.4% 35.3% 33.4% 4.9%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  56.5% 47.6% 55.2% 91.9% 62.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -61.4% -432.3% -34.3% -51.8% 31.1%  
Gearing %  0.0% 0.0% 0.0% 0.0% 17.6%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.2%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  2.1 1.8 2.2 11.8 2.5  
Current Ratio  2.1 1.8 2.2 11.8 2.5  
Cash and cash equivalent  459.4 344.5 230.4 484.5 217.1  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,097.3 1,174.5 1,724.5 2,445.5 1,344.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  249 20 112 134 16  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  249 20 112 134 16  
EBIT / employee  239 16 112 134 16  
Net earnings / employee  185 8 91 105 12